DNA vaccine containing specific epitope of apolipoprotein (a)
AssigneeAnGes, Inc.
InventorsMariko Kyutoku, Hironori Nakagami, Hiroshi Koriyama, Futoshi Nakagami, Ryuichi Morishita
Life of this patent
Estimating the term…
Abstract
The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
Claims22
A method for treating (i) arteriosclerosis or (ii) a disease caused by arteriosclerosis, which disease is selected from a group consisting of cerebral infarction, myocardial infarction, angina, sclerosis obliterans, vascular dementia, and vascular restenosis, said method comprising:
- administering to the mammal an effective amount of an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide,
- wherein the antigen polypeptide comprises the amino acid sequence of SEQ ID NO:
- 1 and the amino acid sequence of SEQ ID NO:
- 1
- is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide,
- wherein expression of the expression vector results in a decrease in lipoprotein (a) deposition and suppresses neointimal thickening, thereby treating (i) arteriosclerosis or (ii) the disease caused by arteriosclerosis, which disease is selected from a group consisting of cerebral infarction, myocardial infarction, angina, sclerosis obliterans, vascular dementia, and vascular restenosis, in the mammal.
A method of inducing a neutralizing antibody against lipoprotein(a) in a mammal, comprising:
- administering an effective amount of an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide to a mammal,
- wherein the antigen polypeptide comprises an amino acid sequence encoded by SEQ ID NO:
- 1 and the amino acid sequence encoded by SEQ ID NO:
- 1
- is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide, and
- wherein expression of the vector induces a neutralizing antibody against lipoprotein (a) in the mammal.
A method of treating arteriosclerosis in a mammal, comprising:
- administering an effective amount of an expression vector to a mammal with arteriosclerosis,
- wherein the expression vector encodes a chimeric hepatitis B virus core antigen polypeptide,
- wherein the antigen polypeptide comprises an amino acid sequence encoded by SEQ ID NO:
- 1 and the amino acid sequence encoded by SEQ ID NO:
- 1
- is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide, and
- wherein the expression of the antigen polypeptide results in a decrease in lipoprotein (a) deposition and suppresses neointimal thickening, thereby treating arteriosclerosis in the mammal.
A method for decreasing lipoprotein (a) deposition and/or neointima formation in a mammal, comprising:
- administering an effective amount of an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide to a mammal,
- wherein the antigen polypeptide comprises an amino acid sequence encoded by SEQ ID NO:
- 1 and the amino acid sequence encoded by SEQ ID NO:
- 1
- is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide, and
- wherein the mammal has (i) arteriosclerosis or (ii) a disease caused by arteriosclerosis, which disease is selected from a group consisting of cerebral infarction myocardial infarction angina sclerosis obliterans vascular dementia and vascular restenosis,
- thereby decreasing lipoprotein (a) deposition and/or neointima formation in the mammal.
Dependencies are inferred from the claim text.